

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the quarter ended 30th September 2022, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited



Itishree Garg
Company Secretary and Compliance Officer
Membership No. A 46259



Date: 13th January 2023